{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:07:24Z","timestamp":1793210844213,"version":"4.5.0"},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Tenecteplase is an alternative to alteplase for emergency treatment of acute ischemic stroke. However, limited data are available comparing their clinical effectiveness in routine clinical practice.<\/jats:p><\/jats:sec>Objective<\/jats:title>To compare short-term effectiveness and safety outcomes for patients with ischemic stroke treated with intravenous tenecteplase vs alteplase.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This comparative effectiveness study used data prospectively collected from July 1, 2020, through June 30, 2022, from the Get With The Guidelines\u2013Stroke registry.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Consecutive patients with ischemic stroke treated with either tenecteplase or alteplase within 4.5 hours from last known well time were included.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary end point was functional independence on discharge (modified Rankin Scale [mRS] score, 0-2). Secondary effectiveness end points included disability free at discharge (mRS score, 0-1), discharge home, and independent ambulation at discharge. Safety end points included symptomatic intracranial hemorrhage (sICH) within 36 hours and combined in-hospital mortality or hospice discharge. Generalized linear mixed models were fit to evaluate associations between exposure to tenecteplase (vs alteplase) and end points after adjustment for demographic, clinical, and hospital-level variables. Adjusted odds ratios (AORs) with 95% CIs were computed.<\/jats:p><\/jats:sec>Results<\/jats:title>Among 79\u202f550 patients treated with intravenous thrombolysis, the mean (SD) age was 68.6 (14.8) years, 38\u202f596 (48.5%) were female, and the median National Institutes of Health Stroke Scale (NIHSS) score was 7 (IQR, 4-13). Of these patients, 9465 (11.9%) received tenecteplase (mean [SD] age, 69.6 [14.7] years; median NIHSS score, 7 [IQR, 4-14]; 4504 [47.6%] female) and 70\u202f085 (88.1%) received alteplase (mean [SD] age, 68.5 [14.8] years; median NIHSS score, 7 [IQR, 4-13]; 34\u202f092 [48.6%] female). After adjustment for covariates, no significant differences were found between tenecteplase and alteplase in effectiveness or safety outcomes for the overall cohort, including functional independence at discharge (AOR, 1.00; 95% CI, 0.93-1.07), sICH (AOR, 0.96; 95% CI, 0.83-1.11), and in-hospital mortality or hospice discharge (AOR, 0.98; 95% CI, 0.89-1.07), but significant improvement was found in discharge home (AOR, 1.26; 95% CI, 1.03-1.53), in-hospital mortality (AOR, 0.63; 95% CI, 0.47-0.85), and composite in-hospital mortality or hospice discharge (AOR, 0.78; 95% CI, 0.62-0.97) among those who were eligible for but did not undergo endovascular thrombectomy.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This large, nationwide comparative effectiveness study using data from routine clinical practice demonstrated similar effectiveness and safety outcomes with tenecteplase compared with alteplase in patients with acute ischemic stroke. This study supports tenecteplase as a reasonable alternative to alteplase.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.0548","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T15:01:02Z","timestamp":1741791662000},"page":"e250548","source":"Crossref","is-referenced-by-count":20,"title":["Short-Term Safety and Effectiveness for Tenecteplase and Alteplase in Acute Ischemic Stroke"],"prefix":"10.1001","volume":"8","author":[{"given":"Justin F.","family":"Rousseau","sequence":"first","affiliation":[{"name":"Biostatistics and Clinical Informatics Section, Department of Neurology, University of Texas Southwestern Medical Center, Dallas"},{"name":"Peter O\u2019Donnell Jr Brain Institute, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy M.","family":"Weber","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Alhanti","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Saver","sequence":"additional","affiliation":[{"name":"Department of Neurology, Geffen School of Medicine at UCLA, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Mess\u00e9","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee H.","family":"Schwamm","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yale University School of Medicine, New Haven, Connecticut"},{"name":"Department of Biomedical Informatics and Data Science, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Ronald Reagan-UCLA Medical Center, Los Angeles, California"},{"name":"Associate Section Editor, JAMA Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin N.","family":"Sheth","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yale University School of Medicine, New Haven, Connecticut"},{"name":"Department Neurosurgery, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric E.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Mullen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisele Sampaio","family":"Silva","sequence":"additional","affiliation":[{"name":"Department of Neurology, Federal University of S\u00e3o Paulo (UNIFESP) and Hospital Israelita Albert Einstein, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Mac Grory","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"},{"name":"Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xian","sequence":"additional","affiliation":[{"name":"Biostatistics and Clinical Informatics Section, Department of Neurology, University of Texas Southwestern Medical Center, Dallas"},{"name":"Peter O\u2019Donnell Jr Brain Institute, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Warach","sequence":"additional","affiliation":[{"name":"Department of Neurology, Dell Medical School, The University of Texas at Austin"},{"name":"Ascension Texas, Austin, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"issue":"10440","key":"zoi250046r1","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","article-title":"Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.","volume":"403","author":"Naghavi","year":"2024","journal-title":"Lancet"},{"issue":"10440","key":"zoi250046r2","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","article-title":"Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.","volume":"403","author":"Ferrari","year":"2024","journal-title":"Lancet"},{"issue":"15","key":"zoi250046r3","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1212\/WNL.0000000000004486","article-title":"Quality improvement in neurology.","volume":"89","author":"Latorre","year":"2017","journal-title":"Neurology"},{"issue":"8","key":"zoi250046r4","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1161\/STROKEAHA.119.025080","article-title":"Evidence that tenecteplase is noninferior to alteplase for acute ischemic stroke: meta-analysis of 5 randomized trials.","volume":"50","author":"Burgos","year":"2019","journal-title":"Stroke"},{"issue":"1","key":"zoi250046r5","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1161\/STROKEAHA.120.030220","article-title":"Intravenous thrombolysis with tenecteplase in patients with large vessel occlusions: systematic review and meta-analysis.","volume":"52","author":"Katsanos","year":"2021","journal-title":"Stroke"},{"issue":"11","key":"zoi250046r6","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1161\/STROKEAHA.120.029749","article-title":"Tenecteplase thrombolysis for acute ischemic stroke.","volume":"51","author":"Warach","year":"2020","journal-title":"Stroke"},{"issue":"10377","key":"zoi250046r7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S0140-6736(22)02600-9","article-title":"Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial.","volume":"401","author":"Wang","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"zoi250046r8","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2320285","article-title":"Tenecteplase versus alteplase for the treatment of acute ischemic stroke: a meta-analysis of randomized controlled trials.","volume":"56","author":"Huang","year":"2024","journal-title":"Ann Med"},{"issue":"8","key":"zoi250046r9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S1474-4422(24)00206-0","article-title":"Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4\u00b75 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial.","volume":"23","author":"Parsons","year":"2024","journal-title":"Lancet Neurol"},{"issue":"7","key":"zoi250046r10","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/S0149-2918(01)80086-2","article-title":"Tenecteplase: a review.","volume":"23","author":"Davydov","year":"2001","journal-title":"Clin Ther"},{"issue":"10","key":"zoi250046r11","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.medj.2022.09.005","article-title":"The promise of tenecteplase in acute stroke: within reach or beyond approval?","volume":"3","author":"Zachrison","year":"2022","journal-title":"Med"},{"key":"zoi250046r12","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/358640","article-title":"Bolus-infusion delays of alteplase during thrombolysis in acute ischaemic stroke and functional outcome at 3 months.","volume":"2014","author":"Acheampong","year":"2014","journal-title":"Stroke Res Treat"},{"issue":"3","key":"zoi250046r13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/WNF.0000000000000081","article-title":"How to manage thrombolysis interruptions in acute stroke?","volume":"38","author":"Brodoehl","year":"2015","journal-title":"Clin Neuropharmacol"},{"issue":"14","key":"zoi250046r14","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1001\/jama.293.14.1746","article-title":"Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes.","volume":"293","author":"Mehta","year":"2005","journal-title":"JAMA"},{"issue":"1","key":"zoi250046r15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0002-9149(02)02387-1","article-title":"Comparison of errors in estimating weight and in dosing of single-bolus tenecteplase with tissue plasminogen activator (TIMI 10B and ASSENT I).","volume":"90","author":"Murphy","year":"2002","journal-title":"Am J Cardiol"},{"issue":"2","key":"zoi250046r16","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1136\/svn-2017-000092","article-title":"The American Heart Association\u2019s Get With the Guidelines (GWTG)\u2013Stroke development and impact on stroke care.","volume":"2","author":"Ormseth","year":"2017","journal-title":"Stroke Vasc Neurol"},{"issue":"2","key":"zoi250046r17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.52927","article-title":"Trends in stroke thrombolysis care metrics and outcomes by race and ethnicity, 2003-2021.","volume":"7","author":"Man","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi250046r18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/0962280206074463","article-title":"Multiple imputation of discrete and continuous data by fully conditional specification.","volume":"16","author":"van Buuren","year":"2007","journal-title":"Stat Methods Med Res"},{"key":"zoi250046r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2024.122912","article-title":"Efficacy and safety outcomes of tenecteplase versus alteplase for thrombolysis of acute ischemic stroke: a meta-analysis of 9 randomized controlled trials.","volume":"458","author":"Wang","year":"2024","journal-title":"J Neurol Sci"},{"issue":"1","key":"zoi250046r20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/23969873221150022","article-title":"European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke.","volume":"8","author":"Alamowitch","year":"2023","journal-title":"Eur Stroke J"},{"issue":"9","key":"zoi250046r21","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.031692","article-title":"Comprehensive review of tenecteplase for thrombolysis in acute ischemic stroke.","volume":"13","author":"Wang","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"zoi250046r22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.4506","article-title":"Off-label use of tenecteplase for the treatment of acute ischemic stroke: a systematic review and meta-analysis.","volume":"5","author":"Katsanos","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"7","key":"zoi250046r23","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamaneurol.2023.1449","article-title":"Symptomatic intracranial hemorrhage with tenecteplase vs alteplase in patients with acute ischemic stroke: the Comparative Effectiveness of Routine Tenecteplase vs Alteplase in Acute Ischemic Stroke (CERTAIN) Collaboration.","volume":"80","author":"Warach","year":"2023","journal-title":"JAMA Neurol"},{"issue":"5","key":"zoi250046r24","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3233\/RNN-150531","article-title":"Discharge destination after acute hospitalization strongly predicts three month disability outcome in ischemic stroke.","volume":"33","author":"Zhang","year":"2015","journal-title":"Restor Neurol Neurosci"},{"issue":"1","key":"zoi250046r25","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000255974","article-title":"Day-90 acute ischemic stroke outcomes can be derived from early functional activity level.","volume":"29","author":"Ovbiagele","year":"2010","journal-title":"Cerebrovasc Dis"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2831320\/rousseau_2025_oi_250046_1741195256.3431.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T15:01:04Z","timestamp":1741791664000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2831320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.0548","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]}}}